Shenzhen Kexing Pharmaceutical Co., Ltd.

Kexing Biopharm is an innovative biopharmaceutical enterprise primarily engaged in the integrated research and development, production, and sales of recombinant protein drugs and microecological preparations. It focuses on drug development in therapeutic areas such as antiviral, blood, tumor and immunity, and degenerative diseases, and has accumulated certain technical expertise in traditional Chinese medicine and chemical drugs around these therapeutic areas.
Kexing Biopharm's main products include recombinant protein drugs "Recombinant Human Erythropoietin", "Recombinant Human Interferon α1b", and "Recombinant Human Granulocyte Colony-stimulating Factor", as well as the microecological preparation drug "Clostridium butyricum dual live bacteria". The company's main products have established a certain industry-leading position and market influence, and in recent years, relying on policy support and deep cultivation of marketing channels, it has maintained stable growth.
After more than twenty years of pharmaceutical research and development and industrialization technology accumulation, Kexing Biopharm has built a relatively complete drug research and development innovation system, covering pharmaceutical innovation capabilities from drug discovery, pharmaceutical research, preclinical research, clinical research to industrialization. Kexing Biopharm's Technology Center was recognized as "Shandong Provincial Enterprise Technology Center" in 2017, as "Jinan Protein Drug Engineering Laboratory" in 2018, and as "Guangdong Province Genetic Engineering Recombinant Protein Drug Engineering Technology Center" in 2020.
Looking to the future, Kexing Biopharm will uphold the development mission of "lean pharmaceutical manufacturing, lean medication, guarding health", focus on the biopharmaceutical development strategy, and continuously advance in research and development, industrialization, marketing, talent and organization to ensure the implementation of the biopharmaceutical development strategy.